115 related articles for article (PubMed ID: 22356895)
1. MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Vivenza D; Gasco M; Monteverde M; Lattanzio L; Syed N; Colantonio I; Denaro N; Natoli G; Comino A; Russi E; Merlano M; Crook T; Lo Nigro C
Oral Oncol; 2012 Jul; 48(7):602-7. PubMed ID: 22356895
[TBL] [Abstract][Full Text] [Related]
2. Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.
Vivenza D; Monteverde M; Lattanzio L; Tonissi F; Astesana V; Denaro N; Comino A; Russi E; Lo Nigro C; Merlano M
Int J Biol Markers; 2016 May; 31(2):e183-92. PubMed ID: 26916894
[TBL] [Abstract][Full Text] [Related]
3. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
[TBL] [Abstract][Full Text] [Related]
4. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
Cescon DW; Bradbury PA; Asomaning K; Hopkins J; Zhai R; Zhou W; Wang Z; Kulke M; Su L; Ma C; Xu W; Marshall AL; Heist RS; Wain JC; Lynch TJ; Christiani DC; Liu G
Clin Cancer Res; 2009 May; 15(9):3103-9. PubMed ID: 19383811
[TBL] [Abstract][Full Text] [Related]
5. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing.
Huang SF; Chen IH; Liao CT; Wang HM; Liou SH; Hsieh LL
Oral Oncol; 2009 Jan; 45(1):16-22. PubMed ID: 18487080
[TBL] [Abstract][Full Text] [Related]
7. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
[TBL] [Abstract][Full Text] [Related]
9. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
Liu L; Wu C; Wang Y; Zhong R; Duan S; Wei S; Lin S; Zhang X; Tan W; Yu D; Nie S; Miao X; Lin D
J Thorac Oncol; 2011 Nov; 6(11):1793-800. PubMed ID: 21841506
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y
Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345
[TBL] [Abstract][Full Text] [Related]
11. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma.
Hong Y; Miao X; Zhang X; Ding F; Luo A; Guo Y; Tan W; Liu Z; Lin D
Cancer Res; 2005 Oct; 65(20):9582-7. PubMed ID: 16230424
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Skjønsberg G; Aas T; Schlichting E; Fjösne HE; Nysted A; Lillehaug JR; Lønning PE
PLoS One; 2011 Apr; 6(4):e19249. PubMed ID: 21556366
[TBL] [Abstract][Full Text] [Related]
13. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.
Koch WM; Brennan JA; Zahurak M; Goodman SN; Westra WH; Schwab D; Yoo GH; Lee DJ; Forastiere AA; Sidransky D
J Natl Cancer Inst; 1996 Nov; 88(21):1580-6. PubMed ID: 8901856
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
Adkins D; Ley J; Trinkaus K; Thorstad W; Lewis J; Wildes T; Siegel BA; Dehdashti F; Gay H; Mehan P; Nussenbaum B
Cancer; 2013 Feb; 119(4):766-73. PubMed ID: 22991252
[TBL] [Abstract][Full Text] [Related]
15. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.
Temam S; Flahault A; Périé S; Monceaux G; Coulet F; Callard P; Bernaudin JF; St Guily JL; Fouret P
J Clin Oncol; 2000 Jan; 18(2):385-94. PubMed ID: 10637254
[TBL] [Abstract][Full Text] [Related]
16. Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.
Vlatković N; El-Fert A; Devling T; Ray-Sinha A; Gore DM; Rubbi CP; Dodson A; Jones AS; Helliwell TR; Jones TM; Boyd MT
Cancer; 2011 Jul; 117(13):2939-50. PubMed ID: 21692053
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
19. Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma.
Nakashima M; Kondo S; Shimizu Y; Wakisaka N; Murono S; Furukawa M; Yoshizaki T
Acta Otolaryngol; 2008 Jul; 128(7):808-13. PubMed ID: 18568525
[TBL] [Abstract][Full Text] [Related]
20. A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Specenier PM; Weyler J; Van Laer C; Van den Weyngaert D; Van den Brande J; Huizing MT; Altintas S; Vermorken JB
BMC Cancer; 2009 Aug; 9():273. PubMed ID: 19660134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
